by Sermonix Pharmaceuticals | Dec 13, 2021 | News
Poster describes pre-clinical findings that lasofoxifene alone or in combination with a CDK inhibitor may limit tumor progression in aromatase inhibitor (AI) resistant tumors not resistant due to an ESR1 mutation December 13, 2021 10:00 ET | Source: Sermonix...
by Sermonix Pharmaceuticals | Nov 16, 2021 | News
Funds will be used to further advance lasofoxifene through late-stage clinical development as a next-generation oral SERM to treat women with increasingly prevalent ESR1 breast cancer mutationsInitial data from both Phase 2 clinical trials is expected in H1 2022...
by Sermonix Pharmaceuticals | Jun 28, 2021 | News
COLUMBUS, Ohio, June 28, 2021 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers, today announced that enrollment has...
by Sermonix Pharmaceuticals | May 19, 2021 | News
Paper highlights the ability of lasofoxifene to inhibit primary tumor growth and reduce metastases in mouse models, both as monotherapy and in combination with palbociclibStudy results demonstrate potential of lasofoxifene as a next-generation selective estrogen...
by Sermonix Pharmaceuticals | Apr 21, 2021 | News
Preclinical effort will examine effect of lasofoxifene on unique endometrial cancer models carrying ESR1 mutations COLUMBUS, Ohio, April 21, 2021 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative...
Recent Comments